Femati®

Letrozole 2.5 mg

Therapeutic category: antineoplastic and immunomodulator agent

Pharmacological category: aromatase inhibitor

Generic name: letrozole

Dosage form: 30 tablets

Strength: 2.5 mg

Indications:

• Adjuvant treatment of hormone receptor-positive early breast cancer
• Extended adjuvant treatment of early breast cancer after 5 years of adjuvant tamoxifen therapy
• First-line treatment of hormone receptor-positive, locally-advanced or metastatic breast cancer
• Treatment of advanced breast cancer in patients with disease progression following antiestrogen therapy
• Breast cancer, high-risk, hormone receptor–positive, adjuvant endocrine therapy in premenopausal patients (in combination with ovarian function suppression)
• Breast cancer in male patients, hormone receptor–positive
• Ovarian (epithelial) cancer, recurrent
• Ovulation induction in patients with polycystic ovary syndrome and anovulatory infertility

This medication must be used only as prescribed by a doctor. Do not use it without a prescription.